Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Mudcat who wrote (17373)	3/13/1998 7:48:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 32384

I suspect that it's both science and resources that helps drive some of these combos, but in general, most of the treatments of the future will be combinations. LGND's most advanced (in a clinical sense) areas are Rexinoids and SERMs and experimental systems indicate that the two classes of drugs synergize. In general, LGND does some of this piggybacking with most of their programs that are with Alliance partners. The Alliance partner moves the drug through expensive trials targeting large markets and then LGND has the right to license back the drug for cancer indications. ZEN's Tamoxifen is the hormonal treatment of choice for breast cancer. The market is in the $1/2 - 3/4 Billion range (in the US?) and Targretin or Panretin could certainly be sold to a similar population, possibly at a higher price. The SERMs are also expected to be very big. LGND has three programs going with Alliance partners (Droloxifene and CP-366,156 with PFE, TSE424 with AHP, and Evista/Raloxifene with LLY) and targeted diseases include osteoporosis and breast cancer at this time, but Alzheimer's, baldness, and memory are additional potential applications.

To: Mudcat who wrote (17373)	3/13/1998 8:29:00 AM
From: Henry Niman	Respond to of 32384

Here's more on estrogen and the brain: Thursday March 12 1:41 PM EST Estrogen And Brain Function: More Data Needed NEW YORK (Reuters) -- Several studies have suggested that estrogen replacement therapy in postmenopausal women can improve cognitive function, cut down on risk of developing dementia, and -- if dementia does occur -- lessen its severity. But other studies have found no such effects. After reviewing relevant published studies, a team of San Francisco researchers conclude that more data is needed before estrogen can be recommended as a therapy to prevent dementia. Dr. Kristine Yaffe, along with her colleagues from the University of California, San Francisco, conducted an exhaustive search of the medical literature from 1966 through 1997. They looked at the results of studies that focused on the effects on cognition (memory and learning) or on the risk of dementia in patients taking estrogen. They then evaluated the conclusions of those studies and the methods researchers used to come to those conclusions. The studies suggest several mechanisms by which estrogen might affect cognition: by promoting neurochemical activity in specific regions of the brain; by keeping neurons in good repair; by affecting lipoproteins in positive ways; or by maintaining circulation in the brain. The researchers found 13 studies published since 1966 that addressed the effect of estrogen on cognitive function in healthy postmenopausal women. "The largest and most methodologically sound observational study of the effect of estrogen use on cognition in nondemented women showed no benefit," the researchers write. A combined analysis of 10 studies looking at the effects of estrogen use in preventing dementia indicates that estrogen use cuts a woman's chances of developing dementia by 29%. But the researchers caution that results from those studies were diverse, so that combining the data may not produce the most accurate figures. Looking at four trials of estrogen use in women with Alzheimer's disease, the team found that all four had essentially positive results. But they say those studies were small and of short duration and that they were neither randomized nor controlled. The authors conclude that although the studies they evaluated provide plausible reasons to believe that estrogen replacement may improve cognitive function, decrease risks of dementia, or lessen the severity of dementia, there are nonetheless "substantial methodologic problems" with that research. They say large, placebo-controlled trials are needed to sort out estrogen's role in preventing and treating Alzheimer's and other forms of dementia. But until then? "Given the known risks of estrogen therapy, we do not recommend estrogen for the prevention or treatment of Alzheimer disease or other dementias until adequate trials have been completed," the researchers conclude. SOURCE: The Journal of the American Medical Association (1998;279:688-695)

To: Mudcat who wrote (17373)	3/13/1998 9:03:00 AM
From: Henry Niman	Respond to of 32384

Speaking of combo's, I just ran across this: Retin-A / Tretinoin <<Retin-A has long been known to improve the results of Minoxidil. Retin-A is generally used for acne and scar and skin condition improvement. Using Retin-A premixed with Minoxidil or applying them separately can greatly improve the results of Minoxidil. We are now offering Retin-A in a cream or lotion. Retin-A purchased separately should be applied separately. If you mix them together, you will weaken them. Several doctors have recommended applying Retin-A, then waiting 15 minutes or until the hair is dry and applying Minoxidil.>> The above was listed at a site that sells medications for male pattern baldness. Some experimental data suggested that estrogen could stimulate hair growth. Thus a SERM/Rexinoid or Retinoid combo might be interesting for the treatment of male pattern baldness.